Nisa Investment Advisors LLC Acquires 236,029 Shares of Johnson & Johnson $JNJ

Nisa Investment Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 32.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 954,381 shares of the company’s stock after purchasing an additional 236,029 shares during the quarter. Johnson & Johnson accounts for approximately 0.7% of Nisa Investment Advisors LLC’s investment portfolio, making the stock its 12th biggest holding. Nisa Investment Advisors LLC’s holdings in Johnson & Johnson were worth $176,961,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Next Level Private LLC grew its stake in Johnson & Johnson by 1.6% in the third quarter. Next Level Private LLC now owns 3,852 shares of the company’s stock valued at $725,000 after purchasing an additional 60 shares in the last quarter. Harrell Investment Partners LLC boosted its holdings in shares of Johnson & Johnson by 4.1% in the 3rd quarter. Harrell Investment Partners LLC now owns 39,958 shares of the company’s stock valued at $7,409,000 after buying an additional 1,559 shares during the last quarter. Duncker Streett & Co. Inc. boosted its holdings in shares of Johnson & Johnson by 1.1% in the 3rd quarter. Duncker Streett & Co. Inc. now owns 14,875 shares of the company’s stock valued at $2,758,000 after buying an additional 159 shares during the last quarter. Wingate Wealth Advisors Inc. grew its stake in shares of Johnson & Johnson by 8.5% in the third quarter. Wingate Wealth Advisors Inc. now owns 1,984 shares of the company’s stock valued at $368,000 after buying an additional 156 shares in the last quarter. Finally, Invested Advisors acquired a new position in Johnson & Johnson during the third quarter worth $1,223,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 2.6%

Shares of JNJ stock opened at $209.79 on Tuesday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $215.18. The company has a market capitalization of $505.45 billion, a PE ratio of 20.25, a price-to-earnings-growth ratio of 2.10 and a beta of 0.34. The firm has a 50 day moving average price of $203.34 and a two-hundred day moving average price of $185.38. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Ratings Changes

A number of brokerages have commented on JNJ. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, December 11th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a research note on Thursday, December 18th. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Barclays upped their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Finally, HSBC reiterated a “buy” rating and set a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.